

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135

Status	RECRUITING
Phase	Phase 2
Sponsor	Walden Biosciences
Enrollment	96 participants

Key Eligibility Criteria

Inclusion (3)

- Adults, age 18-75 years
- Diagnosis of one of the following glomerular kidney diseases: diabetic nephropathy; primary focal segmental glomerulosclerosis; treatment resistant-minimal change disease; primary IgA nephropathy; primary membranous nephropathy
- eGFR greater than or equal to 30 mL/min/1.73 m²

Exclusion (5)

- Currently pregnant or planning to become pregnant
- History of organ transplantation
- History of alcohol or substance use disorder
- Acute dialysis or acute kidney injury within 6 months of Screening
- Any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all study requirements

Locations (50 total)

Academic Medical Research Institute, Los Angeles, California, United States
Colorado Kidney and Vascular Care, Denver, Colorado, United States
D & H Tamarac Research Center, Tamarac, Florida, United States
... and 47 more locations